SCN1A and Dravet syndrome: While numerous therapeutic approaches to enhance Scn1a gene expression levels are in development or at early stages of clinical trial for treating DS patients, whether and to which extent normalization of Nav1.1 level can rescue the disease phenotype is currently unknown.